Ridgetech Inc (Nasdaq:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, announced on Monday its financial results for the fiscal year ended 31 March 2025.
Revenue totalled USD119.97m, down from USD123.99m in the same period of last year.
Gross profit was USD3.84m, compared to USD4.88m a year earlier, while gross margin was 3.2% compared to 3.9% in the year to 31 March 2024.
Ridgetech reported net income of USD10.20m, or USD1.84 per basic and diluted earnings per share, compared to a net loss of USD4.23m, or USD2.93 per basic and diluted loss per share, for the same period a year ago.
As of 31 March 2025 the company had cash and cash equivalents of USD12.78m, an increase from USD2.30m as of 31 March 2024.
Genomma Lab Internacional announces Q2 2025 results
Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio
Perrigo to divest Dermacosmetics business for up to EUR327m
Bavarian Nordic sells US Priority Review Voucher for USD160m
Bavarian Nordic sells US Priority Review Voucher for USD160m
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal
Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties